EP. 10A: Impact of Trilaciclib on Chemotherapy-Induced Myelosuppression in Patients with ES-SCLC

Xiuning Le, MD, PhD, delved into the background, findings, and next steps of the SOHO-01 study.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

The GigaPath AI model was highlighted for its advanced capabilities in predicting cancer mutations and tumor mutation burden, including those in lung cancer and other malignancies.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

In an updated analysis of the phase 3 CheckMate 77T study, perioperative nivolumab showed event-free survival benefits for the treatment of resectable non–small cell lung cancer.

Adagrasib demonstrated superior outcomes to docetaxel in patients with previously treated KRAS G12C-mutated non-small cell lung cancer, even among those with baseline brain metastases.